News | September 30, 2007

New Heart Failure Diagnostic Test Launched

October 1, 2007 - BioMerieux, a developer of in vitro diagnostics, announced the launch of VIDAS NT-proBNP, a CE-approved test that helps the diagnosis and prognosis of heart failure, developed by the company following a licensing agreement signed with Roche Diagnostics.

VIDAS NT-proBNP (N-terminal pro-B-type natriuretic peptide), a quantitative marker of heart stress, reportedly provides objective diagnostic information that helps distinguish heart failure from other disease states with similar clinical symptoms, for instance lung diseases or pulmonary embolism. The company says it has the potential to detect early stages of heart failure in the absence of clinically obvious symptoms. In addition, it can be used to assess the prognosis of patients with established heart failure or acute coronary syndrome.

The VIDAS design reportedly makes this assay available 24 hours a day for emergency departments.

For more information: www.bioMerieux.com


Additional Content

News | Mobile C-Arms

June 19, 2024 —Royal Philips, a global leader in health technology, today announced the launch of Philips Image Guided ...

Home June 20, 2024
Home
News | Mobile C-Arms

March 21, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of the CIARTIC Move, a ...

Home March 21, 2024
Home
News | Mobile C-Arms

July 29, 2022 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the ARTIS icono ...

Home July 29, 2022
Home
News | Mobile C-Arms

August 18, 2020 — Ziehm Imaging announces the acquisition of Therenva, a French-based developer of planning and imaging ...

Home August 18, 2020
Home
Technology | Mobile C-Arms

February 18, 2019 — Philips announced the launch of Philips Zenition, its new mobile C-arm imaging platform. Mobile C ...

Home February 18, 2019
Home
Subscribe Now